Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Neurogene (NGNE) Return on Equity (2019 - 2025)

Historic Return on Equity for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to 0.32%.

  • Neurogene's Return on Equity rose 1600.0% to 0.32% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.32%, marking a year-over-year increase of 1600.0%. This contributed to the annual value of 0.31% for FY2024, which is N/A changed from last year.
  • Per Neurogene's latest filing, its Return on Equity stood at 0.32% for Q3 2025, which was up 1600.0% from 0.3% recorded in Q2 2025.
  • Neurogene's Return on Equity's 5-year high stood at 0.09% during Q1 2023, with a 5-year trough of 0.5% in Q3 2023.
  • Over the past 3 years, Neurogene's median Return on Equity value was 0.32% (recorded in 2025), while the average stood at 0.34%.
  • As far as peak fluctuations go, Neurogene's Return on Equity tumbled by -2400bps in 2024, and later skyrocketed by 1600bps in 2025.
  • Quarter analysis of 3 years shows Neurogene's Return on Equity stood at 0.4% in 2023, then increased by 16bps to 0.34% in 2024, then increased by 5bps to 0.32% in 2025.
  • Its last three reported values are 0.32% in Q3 2025, 0.3% for Q2 2025, and 0.27% during Q1 2025.